Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data.
OBJECTIVE: Higher serum uric acid (SUA) is associated with diabetic kidney disease (DKD). Preventing Early Renal Loss in Diabetes (PERL) evaluates whether lowering SUA with allopurinol slows glomerular filtration rate (GFR) loss in people with type 1 diabetes (T1D) and mild to moderate DKD. We present the PERL rationale, design, and baseline characteristics.
RESEARCH DESIGN AND METHODS: This double-blind, placebo-controlled, multicenter trial randomized 530 participants with T1D, estimated GFR (eGFR) of 40-99.9 mL/min/1.73 m
RESULTS: Participants are 66% male and 84% white. At baseline, median age was 52 years and diabetes duration was 35 years, 93% of participants had hypertension, and 90% were treated with renin-angiotensin system inhibitors (median blood pressure 127/71 mmHg). Median HbA
CONCLUSIONS: PERL will determine the effect of allopurinol on mild to moderate DKD in T1D, with or without albuminuria. Participants with normoalbuminuria and rapid GFR loss manifested many DKD risk factors of those with albuminuria, but with less severity.
Kidney & Diabetes
Afkarian, Maryam; Polsky, Sarit; Parsa, Afshin; Aronson, Ronnie; Caramori, Maria Luiza; Cherney, David Z; Crandall, Jill P; de Boer, Ian H; Elliott, Thomas G; Galecki, Andrzej T; Goldfine, Allison B; Haw, J Sonya; Hirsch, Irl B; Karger, Amy B; Lingvay, Ildiko; Maahs, David M; McGill, Janet B; Molitch, Mark E; Perkins, Bruce A; Pop-Busui, Rodica; Pragnell, Marlon; Rosas, Sylvia E; Rossing, Peter; Senior, Peter; Sigal, Ronald J; Spino, Catherine; Tuttle, Katherine; Umpierrez, Guillermo E; Wallia, Amisha; Weinstock, Ruth S; Wu, Chunyi; Mauer, Michael; and Doria, Alessandro, "Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data." (2019). Articles, Abstracts, and Reports. 1799.